https://algernonneuroscience.com/repurposed-anti-fibrotic-medication-np-120-set-for-phase-2-testing-for-ipf/2019-08-06T23:32:06+00:00https://algernonneuroscience.com/dr-arun-sanyal/2019-12-19T18:43:03+00:00https://algernonneuroscience.com/dr-walter-reinisch/2019-12-19T18:43:58+00:00https://algernonneuroscience.com/dr-martin-kolb/2019-12-19T18:44:58+00:00https://algernonneuroscience.com/fiercebiotech-algernon-signs-novotech-up-for-midstage-respiratory-therapy-test/2020-02-11T20:19:59+00:00https://algernonneuroscience.com/algernon-pharmaceuticals-begins-screening-patients-for-phase-2-chronic-cough-and-ipf-study/2020-07-10T18:16:53+00:00https://algernonneuroscience.com/test-1/2020-08-23T17:32:13+00:00https://algernonneuroscience.com/algernon-pharmaceuticals-ceo-christopher-moreau-to-present-at-proactives-one2one-virtual-investor-conference-to-be-held-december-8-2020/2020-12-03T19:00:18+00:00https://algernonneuroscience.com/a-letter-from-algernon-pharmaceuticals-ceo-christopher-moreau/2020-12-08T15:28:52+00:00https://algernonneuroscience.com/streetsmart-live-interview-with-ceo-christopher-moreau-and-cso-dr-mark-williams/2020-12-21T20:10:20+00:00https://algernonneuroscience.com/algernon-pharmaceuticals-targets-psychedelic-drug-dmt-for-stroke-program/2021-02-04T22:12:30+00:00https://algernonneuroscience.com/dmt-stroke-research-algernon-pharmaceuticals-moving-to-the-head-of-the-pack/2021-02-04T22:23:50+00:00https://algernonneuroscience.com/algernon-pharmaceuticals-launches-research-program-for-treatment-of-stroke-using-psychedelic-drug-dmt/2021-02-04T22:53:12+00:00https://algernonneuroscience.com/metro-uk-stroke-victims-to-be-given-psychedelic-drug-dmt-in-groundbreaking-study/2021-02-04T23:02:58+00:00https://algernonneuroscience.com/stroke-victims-to-get-hallucinogenic-drug-dmt-to-stave-off-worst-effects-of-life-threatening-condition-in-first-of-its-kind-trial-scientists-say/2021-02-09T20:33:30+00:00https://algernonneuroscience.com/ifl-science-psychedelic-drug-dmt-to-be-trialed-on-stroke-victims/2021-02-10T15:05:02+00:00https://algernonneuroscience.com/proactive-algernon-pharmaceuticals-considers-adding-lung-scarring-for-additional-endpoint-in-ifenprodil-study/2021-02-11T21:57:44+00:00https://algernonneuroscience.com/bnn-bloomberg-how-algernon-pharmaceuticals-is-aiming-to-use-psychedelics-to-aid-stroke-recovery/2021-02-18T16:40:26+00:00https://algernonneuroscience.com/psychedelic-capital-virtual-investment-conference-feb-2021-microdose/2021-02-28T22:37:17+00:00https://algernonneuroscience.com/microdose-psycap-conference-investment-opportunities-and-new-companies-in-the-sector/2021-02-28T22:44:50+00:00https://algernonneuroscience.com/algernon-pharmaceuticals-looks-to-highly-regarded-uk-company-to-conduct-phase-1-dmt-stroke-study/2021-03-02T20:18:09+00:00https://algernonneuroscience.com/algernon-ceo-christopher-moreau-and-consultant-dr-david-nutt-discuss-the-dmt-stroke-program-on-biopub-webcast-hosted-by-dr-kss-md-phd/2021-03-04T16:09:39+00:00https://algernonneuroscience.com/could-the-spirit-molecule-dmt-assist-in-stroke-recovery-technology-network/2021-03-12T04:06:20+00:00https://algernonneuroscience.com/dmt-update-and-recap-interview-with-ceo-christopher-moreau-and-host-cyndi-edwards-of-prmedianow/2021-03-18T22:15:14+00:00https://algernonneuroscience.com/proactive-interview-regarding-50-enrollment-into-the-ipf-chronic-cough-and-the-announcement-that-ifenprodil-has-reduced-interlukin-6-in-the-recent-ifenprodil-phase-2b-3-covid-19-trial/2021-05-12T21:09:31+00:00https://algernonneuroscience.com/psychedelic-finance-interview-with-professor-david-nutt-algernon-pharmaceuticals-dmt-stroke-consultant/2021-04-30T21:21:11+00:00https://algernonneuroscience.com/interview-with-algernon-pharmaceuticals-ceo-christopher-j-moreau-about-new-dmt-stroke-program/2021-04-13T21:29:31+00:00https://algernonneuroscience.com/algernon-pharmaceuticals-dmt-stroke-program-update-and-recap-with-ceo-christopher-moreau/2021-03-19T21:32:37+00:00https://algernonneuroscience.com/algernon-pharmaceuticals-dmt-clinical-research-program-for-stroke-receives-positive-fda-feedback/2021-05-17T15:34:32+00:00https://algernonneuroscience.com/prmedianow-algernon-pharmaceuticals-update-with-ceo-christopher-moreau/2021-05-13T15:39:09+00:00https://algernonneuroscience.com/7806-2/2021-05-22T13:04:48+00:00https://algernonneuroscience.com/psychedelic-finance-interview-with-dr-rick-strassman-dmt-stroke-program-consultant-algernon-pharmaceuticals/2021-05-21T12:53:36+00:00https://algernonneuroscience.com/stockhouse-algernon-pharmaceuticals-makes-major-headway-toward-clinical-trials-for-treatment-of-stroke/2021-06-22T12:57:01+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-phase-2-human-study-of-ifenprodil-for-ipf-and-chronic-cough-is-now-70-enrolled/2021-07-07T17:04:15+00:00https://algernonneuroscience.com/streetwise-live-algernon-pharmaceuticals-ceo-christopher-moreau-and-dr-david-nutt-discuss-phase-1-dmt-study-for-stroke/2021-07-09T12:52:11+00:00https://algernonneuroscience.com/upfront-with-algernon-pharmaceuticals-ceo/2021-08-24T16:34:17+00:00https://algernonneuroscience.com/psychedelic-finance-interview-with-christopher-j-moreau-chief-executive-officer-algernon-pharmaceuticals/2021-09-07T12:54:55+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-preclinical-study-of-dmt-for-stroke-confirms-growth-of-neurons-by-40/2021-09-07T18:11:26+00:00https://algernonneuroscience.com/upfront-with-algernon-pharmaceuticals-ceo-ep-2/2021-09-11T13:16:40+00:00https://algernonneuroscience.com/the-dales-report-preclinical-study-shows-microdoses-of-dmt-increased-growth-of-neurons/2021-09-13T13:22:28+00:00https://algernonneuroscience.com/upfront-with-algernon-pharmaceuticals-ceo-chistopher-j-moreau-episode-3/2021-09-23T13:24:35+00:00https://algernonneuroscience.com/dmt-increases-growth-of-rat-neurons-by-40-percent-new-data-shows/2021-09-27T14:13:59+00:00https://algernonneuroscience.com/powerplay-by-the-market-herald-interviews-christopher-j-moreau-ceo/2023-03-26T21:22:10+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-establishes-optimum-treatment-period-for-dmt/2023-03-26T21:21:54+00:00https://algernonneuroscience.com/algernon-presents-psychiatrist-and-author-rick-strassman-md-on-a-special-biopub-webcast-hosted-by-dr-kss-md-phd/2023-03-26T21:21:27+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-receives-positive-feedback-on-its-planned-phase-1-2a-dmt-human-stroke-stud/2023-03-26T21:21:10+00:00https://algernonneuroscience.com/upfront-with-algernon-pharmaceuticals-ceo-chistopher-j-moreau-episode-4/2023-03-26T21:20:52+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-receives-a-positive-response-from-u-s-fda-on-sclc-study/2023-03-26T21:20:34+00:00https://algernonneuroscience.com/market-one-rethinking-dmt-algernon-pharmaceuticals-novel-approach-to-stroke-treatment/2023-03-26T21:20:18+00:00https://algernonneuroscience.com/streetwise-reports-algernon-pharmaceuticals-looks-to-u-s-for-help-fighting-strokes/2023-03-26T21:19:49+00:00https://algernonneuroscience.com/algernon-pharmaceuticals-ifenprodil-chronic-cough-study-receives-positive-feedback-from-u-s-fda/2023-03-26T21:19:28+00:00https://algernonneuroscience.com/this-pharmaceutical-company-has-a-brilliant-concept-an-expert-opinion/2023-03-26T21:19:11+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-files-for-clinical-trial-and-ethics-approval-for-phase-1-dmt-stroke-study/2023-03-26T21:18:47+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-discloses-novel-salt-patent-strategy-for-dmt-intellectual-property/2023-03-26T21:18:26+00:00https://algernonneuroscience.com/streetwise-live-algernon-is-awaiting-approval-for-a-phase-1-dmt-human-stroke-study/2023-03-26T21:17:59+00:00https://algernonneuroscience.com/business-television-algernon-pharmaceuticals-and-the-dmt-stroke-clinical-program/2023-03-26T21:17:27+00:00https://algernonneuroscience.com/algernon-pharmaceuticals-phase-1-dmt-stroke-study-will-start-in-september-2022/2023-03-26T21:17:08+00:00https://algernonneuroscience.com/algernon-pharmaceuticals-provides-update-on-chronic-kidney-disease-research-program-with-np-251/2023-03-26T21:14:33+00:00https://algernonneuroscience.com/streetwise-reports-can-the-psychedelic-drug-dmt-take-algernon-to-the-next-level/2023-03-26T21:14:11+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-study-of-ifenprodil-for-the-treatment-of-ipf-and-chronic-cough-reaches-key-stage/2023-03-26T21:03:55+00:00https://algernonneuroscience.com/streetwise-reports-patients-in-algernons-phase-2a-study-show-improved-lung-capacity/2023-03-26T20:54:54+00:00https://algernonneuroscience.com/pulmonary-fibrosis-news-np-120-potential-ipf-treatment-stabilizes-lung-function-in-trial/2023-03-26T20:30:33+00:00https://algernonneuroscience.com/medicalgold-ca-algernon-rapidly-advances-clinical-trials-for-two-lead-programs/2023-03-26T20:13:18+00:00https://algernonneuroscience.com/streetwise-reports-hedge-fund-doubles-position-in-biotech-co/2023-03-26T20:24:00+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-releases-positive-data-from-study-on-ifenprodil-for-ipf-and-chronic-cough/2023-03-26T20:22:03+00:00https://algernonneuroscience.com/streetwise-reports-will-pharma-co-keep-pushing-higher-after-full-data-set-released-on-lung-disease-study/2023-03-26T20:16:42+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-gains-approval-for-phase-1-clinical-study-of-dmt-for-treatment-of-stroke/2023-03-26T20:05:03+00:00https://algernonneuroscience.com/pulmonary-fibrosis-news-orphan-drug-status-sought-for-np-120-to-treat-ipf-with-cough/2023-03-26T20:01:23+00:00https://algernonneuroscience.com/mugglehead-magazine-algernon-receives-approval-to-conduct-dmt-study-in-the-netherlands/2023-03-26T19:56:55+00:00https://algernonneuroscience.com/radius-research-algernon-pharmaceuticals-agn-ceo-christopher-j-moreau-business-update-ifenprodil-dmt-trials/2023-03-26T19:32:56+00:00https://algernonneuroscience.com/high-times-new-research-exploring-dmt-as-a-treatment-for-stroke/2023-03-26T19:29:43+00:00https://algernonneuroscience.com/drug-discovery-and-development-dmt-pioneer-rick-strassman-weighs-in-on-psychedelic-hope-and-hype/2023-03-26T19:25:30+00:00https://algernonneuroscience.com/psychedelic-spotlight-prolonged-dmt-infusions-could-be-a-breakthrough-for-stroke-patients/2023-03-26T19:20:21+00:00https://algernonneuroscience.com/radius-research-algernon-pharmaceuticals-agn-ceo-christopher-j-moreau-yale-clinical-trial-for-dmt-phase-2-depression-study/2023-03-26T19:13:54+00:00https://algernonneuroscience.com/bnn-bloomberg-in-a-sector-ripe-for-revival-algernons-development-pipeline-positions-it-well/2023-03-26T19:08:53+00:00https://algernonneuroscience.com/born2invest-algernon-pharmaceuticals-is-developing-pioneering-treatments-with-a-cost-efficient-rd-pipeline/2023-03-26T19:04:56+00:00https://algernonneuroscience.com/market-one-algernon-pharmaceuticals-receives-approval-for-groundbreaking-phase-1-study-of-dmt-for-stroke/2023-03-26T18:56:48+00:00https://algernonneuroscience.com/psychedelic-finance-feature-algernon-pharmaceuticals/2023-03-26T18:51:02+00:00https://algernonneuroscience.com/drug-discovery-and-development-why-algernon-believes-it-is-the-janis-joplin-of-psychedelic-medicine-companies/2023-03-26T18:48:58+00:00https://algernonneuroscience.com/psychedelic-finance-feature-christopher-j-moreau-chief-executive-officer-algernon-pharmaceuticals/2023-03-26T18:46:25+00:00https://algernonneuroscience.com/marketone-video-interview-with-ceo-christopher-j-moreau-algernon-pharmaceuticals-is-the-first-to-investigate-dmt-as-a-treatment-for-stroke/2023-03-26T18:10:36+00:00https://algernonneuroscience.com/psychedelic-therapeutics-for-human-stroke-participant-screening-expects-to-begin-soon-for-algernon-pharmaceuticals-dmt-study/2023-03-26T18:05:50+00:00https://algernonneuroscience.com/the-national-investor-repurposing-drugs-for-new-needs-algernon-pharmaceuticals-inc-cse-agn-otcqb-agnpf/2023-03-26T18:01:20+00:00https://algernonneuroscience.com/wonderland-2022-recap-algernon-pharmaceuticals/2023-03-26T17:59:13+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-forms-algernon-neuroscience-subsidiary-to-advance-dmt-stroke-program/2023-03-26T17:36:13+00:00https://algernonneuroscience.com/benzinga-psychedelic-subsidiaries-news-blackhawk-spins-out-three-companies-algernon-creates-a-new-one/2023-03-26T17:31:58+00:00https://algernonneuroscience.com/proactive-investors-interview-algernon-pharmaceuticals-releases-details-of-planned-phase-2b-chronic-cough-study-of-ifenprodil/2023-03-26T17:25:06+00:00https://algernonneuroscience.com/the-market-herald-algernon-pharmaceuticals-announces-upcoming-phase-2b-chronic-cough-study-of-ifenprodil/2023-03-26T17:18:26+00:00https://algernonneuroscience.com/proactive-investors-ceo-interview-algernon-neuroscience-doses-first-patient-in-stroke-study/2023-03-26T17:12:49+00:00https://algernonneuroscience.com/microdose-microdosing-dmt-to-treat-stokes-not-as-trippy-as-it-sounds/2023-03-26T17:04:03+00:00https://algernonneuroscience.com/radius-research-algernon-pharma-agn-ceo-chris-moreau-ap-188-dmt-dimethyltryptamine-program-update/2023-03-26T16:30:41+00:00https://algernonneuroscience.com/radius-research-interview-algernon-pharmaceuticals-agn-ceo-christopher-j-moreau-ifendprodil-program-update-targeting-chronic-cough/2023-03-26T16:25:34+00:00https://algernonneuroscience.com/sr-times-drug-could-possibly-both-reduce-acute-damage-of-the-stroke-how-dmt-could-be-the-future-of-stroke-treatment/2023-03-26T16:17:45+00:00https://algernonneuroscience.com/proactive-investors-ceo-interview-algernon-neuroscience-completes-first-dosing-in-phase-1-clinical-study-of-dmt/2023-03-26T16:08:49+00:00https://algernonneuroscience.com/radius-research-interview-algernon-neuroscience-initiates-tbi-research-program-with-dmt/2023-03-26T16:04:50+00:00https://algernonneuroscience.com/8520-2/2023-03-26T16:36:40+00:00https://algernonneuroscience.com/the-dales-report-why-psychedelic-treatments-will-benefit-investors-and-healthcare/2023-03-26T16:11:48+00:00https://algernonneuroscience.com/how-algernon-pharmaceuticals-is-unlocking-sub-psychedelic-dmt-for-stroke-and-tbi-treatment/2025-03-24T22:58:19+00:00https://algernonneuroscience.com/algernon-ceo-discusses-ifenprodil-sale-to-seyltx-and-dmt-as-a-treatment-for-stroke-and-tbi/2025-03-24T23:10:03+00:00